Case Type: Mergers & Acquisitions

Amplify Energy Corp. (NYSE: AMPY), relating to the proposed merger with Juniper Capital. Under the terms of the agreement, Amplify shareholders will retain approximately 61% of Amplify’s outstanding equity.

ReShape Lifesciences Inc. (Nasdaq: RSLS), relating to the proposed merger with Vyome Therapeutics, Inc. Under the terms of the agreement, ReShape and Vyome will combine in an all-stock transaction, with ReShape stockholders owning approximately 11.1% of the combined company.

Edible Garden AG Incorporated (Nasdaq: EDBL), relating to the proposed merger with Narayan d.o.o. Under the terms of the non-binding letter of intent, in consideration for 100% of the share capital of Narayan, Edible Garden will issue to the Narayan shareholders shares of Edible Garden common stock.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), relating to the proposed merger with Decoy Therapeutics, Inc. Under the terms of the agreement, Salarius stockholders would own approximately 14% of the outstanding shares of the combined company.

H&E Equipment Services, Inc. (Nasdaq: HEES), relating to the proposed merger with Herc Holdings Inc. Under the terms of the agreement, H&E shareholders will receive $78.75 in cash and 0.1287 shares of Herc common stock for each share they own. H&E’s shareholders will own approximately 14.1% of the combined company.

Enfusion, Inc. (NYSE: ENFN), relating to the proposed merger with Clearwater Analytics. Under the terms of the agreement, Enfusion shareholders will receive $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), relating to the proposed merger with Johnson & Johnson. Under the terms of the agreement, Johnson & Johnson will acquire all outstanding shares of Intra-Cellular Therapies for a payment of $132.00 per share in cash.

CNB Financial Corporation (Nasdaq: CCNE), relating to the proposed merger with ESSA Bancorp, Inc. Under the terms of the agreement, ESSA shareholders will receive 0.8547 shares of CNB common stock for each outstanding share of ESSA common stock.

ESSA Bancorp, Inc. (Nasdaq: ESSA), relating to the proposed merger with CNB Financial Corporation. Under the terms of the agreement, ESSA shareholders will receive 0.8547 shares of CNB common stock for each outstanding share of ESSA common stock.

Akoya Biosciences, Inc. (Nasdaq: AKYA), relating to the proposed merger with Quanterix. Under the terms of the agreement, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock owned. Akoya shareholders will own approximately 30% of the combined company.